DAM
BMY.RT

Deltec Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Deltec Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$35K – 348
2020
Q4 		$35K Sell
50,000
-7,098
-12% -$15.1K 0.01% 220
2020
Q3 		$128K Buy
57,098
+35,000
+158% +$100K 0.02% 202
2020
Q2 		$79K Buy
+22,098
New +$79.7K 0.02% 183
2020
Q1 		– Sell
-50,000
Closed -$150K – 206
2019
Q4 		$150K Buy
+50,000
New +$130K 0.03% 164

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Deltec Asset Management's BMY.RT Position: Q1 2021 in Review

Deltec Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 50,000 shares — an estimated $35K sold.

Deltec Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $150K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Deltec Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Deltec Asset Management sold 50,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $35K.
  • Deltec Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Deltec Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $150K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Deltec Asset Management's 13F filing for Q1 2021, filed 21 Apr 2021.